Carol Ashe currently serves as the Chief Business Officer for the New York Genome Center and is responsible for identifying and executing on revenue generating business development opportunities.
Carol is a seasoned executive with over 25 years of experience in pharmaceutical and consumer healthcare business development, corporate development and venture capital. Previously, in addition to providing business development consulting services to early, late and commercial stage biotechnology and pharmaceutical companies, Carol was Vice President of Corporate Development for Endo’s three pharmaceutical business units (Branded, Generics and Implant Drug Delivery Technology). Prior to Endo, Carol was a Partner at SR One (GlaxoSmithKline’s Corporate VC fund) where she helped source and evaluate opportunities, facilitate investments and was a Board Observer for some portfolio companies. Before she joined SR One, Carol was Vice President, Legal Operations Corporate Functions – US at GSK where she led legal support for corporate staff functions in the US including mergers, acquisitions and equity investments. Prior to her corporate legal role, Carol was the Vice President & Associate General Counsel, Head – BD Legal Transactions Team at GSK for many years and led a large, internationally based team that provided business development transactional legal support for GSK’s Pharmaceuticals and Consumer Healthcare businesses on both a US and global basis. Carol is currently a non-executive Director for Aptose Biosciences, a public biotechnology company.
Carol holds a J.D. from the Villanova University School of Law and a B.S. in Biology from the Pennsylvania State University. She is a registered patent attorney with the USPTO.